Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct 12;24(20):3672.
doi: 10.3390/molecules24203672.

Cannabinoid Receptor Interacting Protein 1a (CRIP1a): Function and Structure

Affiliations
Review

Cannabinoid Receptor Interacting Protein 1a (CRIP1a): Function and Structure

William T Booth et al. Molecules. .

Abstract

Cannabinoid receptor interacting protein 1a (CRIP1a) is an important CB1 cannabinoid receptor-associated protein, first identified from a yeast two-hybrid screen to modulate CB1-mediated N-type Ca2+ currents. In this paper we review studies of CRIP1a function and structure based upon in vitro experiments and computational chemistry, which elucidate the specific mechanisms for the interaction of CRIP1a with CB1 receptors. N18TG2 neuronal cells overexpressing or silencing CRIP1a highlighted the ability of CRIP1 to regulate cyclic adenosine 3',5'monophosphate (cAMP) production and extracellular signal-regulated kinase (ERK1/2) phosphorylation. These studies indicated that CRIP1a attenuates the G protein signaling cascade through modulating which Gi/o subtypes interact with the CB1 receptor. CRIP1a also attenuates CB1 receptor internalization via β-arrestin, suggesting that CRIP1a competes for β-arrestin binding to the CB1 receptor. Predictions of CRIP1a secondary structure suggest that residues 34-110 are minimally necessary for association with key amino acids within the distal C-terminus of the CB1 receptor, as well as the mGlu8a metabotropic glutamate receptor. These interactions are disrupted through phosphorylation of serines and threonines in these regions. Through investigations of the function and structure of CRIP1a, new pharmacotherapies based upon the CRIP-CB1 receptor interaction can be designed to treat diseases such as epilepsy, motor dysfunctions and schizophrenia.

Keywords: CP55940; G protein coupled receptor (GPCR); G proteins; WIN55212-2; adenylyl cyclase; computational chemistry; cyclic adenosine 3′,5′monophosphate (cAMP); extracellular signal-regulated kinase (ERK); β-arrestin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(A). Overview of the known structural and biochemical features of the CB1 receptor. The complex between full-length CB1 receptor, agonist MDMB-fubinaca (FUB), and G protein complex, as determined by cryoelectron microscopy (PDB code 6N4B) [32]. The intracellular region interactions are highlighted. Importantly, similar to available crystal structures, no electron density was observed for ICL3 and the C-terminus (residues 412–472). The nuclear magnetic resonance study by Ahn and colleagues supports that residues 440–461 form a second amphipathic helix that can interact with the membrane [33]. Cys415 can be palmitoylated to help anchor the C-terminus to the membrane [34,35]. (B). Primary sequence of the human CB1 receptor ICL3 loop, and C-terminal central and distal regions. The sequence is depicted in the same coloring as Figure 1A. Residues that can be phosphorylated are indicated in bold and underlined. Negatively-charged amino acids are indicated in bold. Five residues in the distal regions of the CB1 and mGlu8a receptors important for CRIP1a binding are boxed in black (see text for details).
Figure 2
Figure 2
Primary sequence of CRIP1a from model organisms. Scientific names and protein codes: Rattus norvegicus (Q5M7A7), Mus musculus (Q5M8N0), Homo sapiens (Q96F85), Bos taurus (Q17QM9), Xenopus laevis (NP_001087998), Danio rerio (NP_001314699). The sequence identity relative to the top sequence proceeds down the alignment: 99%, 95%, 95%, 67%, and 59%.

References

    1. Ligresti A., De P.L., Di Marzo V. From phytocannabinoids to cannabinoid receptors and endocannabinoids: Pleiotropic physiological and pathological roles through complex pharmacology. Physiol. Rev. 2016;96:1593–1659. doi: 10.1152/physrev.00002.2016. - DOI - PubMed
    1. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., et al. International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharm. Rev. 2002;54:161–202. doi: 10.1124/pr.54.2.161. - DOI - PubMed
    1. Luongo L., Starowicz K., Maione S., Di Marzo V. Allodynia lowering induced by cannabinoids and endocannabinoids (ALICE) Pharm. Res. 2017;119:272–277. doi: 10.1016/j.phrs.2017.02.019. - DOI - PubMed
    1. Piscitelli F., Bradshaw H.B. Endocannabinoid analytical methodologies: Techniques that drive discoveries that drive techniques. Adv. Pharm. 2017;80:1–30. - PubMed
    1. Howlett A.C., Abood M.E. CB1 and CB2 receptor pharmacology. Adv. Pharm. 2017;80:169–206. - PMC - PubMed

MeSH terms

LinkOut - more resources